跳至主要内容
临床试验/jRCT2080222103
jRCT2080222103未知3 期

A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)

Parexel International0 个研究点开始时间: 待定

试验速览

阶段
3 期

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • Have completed 52 weeks of treatment in BCDS study

排除标准

  • 未提供

研究者

相似试验

进行中(未招募)
不适用
An Open Label Study for Patients With Rheumatoid Arthritis (FLEX-P)Rheumatoid Arthritis
EUCTR2010-022208-36-BGEli Lilly and Company1,505
进行中(未招募)
1 期
The study will test an experimental drug called B/F/TAF (bictegravir/emtricitabine/tenofovir alafenamide) fixed-dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to evaluate the effectiveness of switching to B/F/TAF FDC in HIV-1 infected adults aged = 65 years who are virologically suppressed (HIV-1 RNA test <50 copies/mL) currently on elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide FDC or tenofovir disoproxil fumarate containing regimens.Human Immunodeficiency Virus (HIV-1) InfectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862
EUCTR2017-003428-61-ESGilead Sciences, Inc.86
进行中(未招募)
不适用
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)MedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid Arthritis
EUCTR2010-022208-36-DEEli Lilly and Company1,505
进行中(未招募)
不适用
Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE).Systemic Lupus Erythematosus (SLE)MedDRA version: 17.0Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859
EUCTR2010-022101-18-HREli Lilly and Company1,276
未知
3 期
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)systemic lupus erythematosus (SLE)
JPRN-jRCT2080222103Parexel International